Reviewing IsoPlexis (NASDAQ:ISO) and BioForce Nanosciences (OTCMKTS:BFNH)

IsoPlexis (NASDAQ:ISOGet Rating) and BioForce Nanosciences (OTCMKTS:BFNHGet Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares IsoPlexis and BioForce Nanosciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IsoPlexis $17.26 million 2.96 -$81.57 million N/A N/A
BioForce Nanosciences N/A N/A -$500,000.00 ($0.01) -285.00

BioForce Nanosciences has lower revenue, but higher earnings than IsoPlexis.

Insider & Institutional Ownership

44.9% of IsoPlexis shares are held by institutional investors. 6.4% of IsoPlexis shares are held by company insiders. Comparatively, 39.5% of BioForce Nanosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares IsoPlexis and BioForce Nanosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IsoPlexis -517.60% -89.63% -57.93%
BioForce Nanosciences N/A N/A -6,104.22%

Risk & Volatility

IsoPlexis has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, BioForce Nanosciences has a beta of -1.62, suggesting that its share price is 262% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for IsoPlexis and BioForce Nanosciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IsoPlexis 0 2 0 0 2.00
BioForce Nanosciences 0 0 0 0 N/A

IsoPlexis currently has a consensus price target of $1.60, suggesting a potential upside of 24.03%. Given IsoPlexis’ higher probable upside, equities research analysts plainly believe IsoPlexis is more favorable than BioForce Nanosciences.


IsoPlexis beats BioForce Nanosciences on 5 of the 9 factors compared between the two stocks.

About IsoPlexis

(Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

About BioForce Nanosciences

(Get Rating)

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. The company is based in Virginia Beach, Virginia.

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with's FREE daily email newsletter.